Lafutidine

From Wikipedia, the free encyclopedia
(Redirected from ATC code A02BA08)
Jump to navigation Jump to search
Lafutidine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Identifiers
  • 2-(furan-2-ylmethylsulfinyl)-N-[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H29N3O4S
Molar mass431.55 g·mol−1
3D model (JSmol)
  • C1CCCCN1Cc2ccnc(c2)OC/C=C\CNC(=O)CS(=O)Cc3ccco3
  • InChI=1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- ☒N
  • Key:KMZQAVXSMUKBPD-DJWKRKHSSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Lafutidine (INN) is a second generation histamine H2 receptor antagonist having multimodal mechanism of action and used to treat gastrointestinal disorders.[1] It is marketed in South Korea, Japan and India.

Medical use

[edit | edit source]

Lafutidine is used to treat gastric ulcers, duodenal ulcers, as well as wounds in the lining of the stomach associated with acute gastritis and acute exacerbation of chronic gastritis.[2][3]

Adverse effects

[edit | edit source]

Adverse events observed during clinical trials included constipation, diarrhea, drug rash, nausea, vomiting and dizziness.[3]

Mechanism of action

[edit | edit source]

Like other H2 receptor antagonists, lafutidine acts by preventing the secretion of gastric acid.[3] It also activates calcitonin gene-related peptide, resulting in the stimulation of nitric oxide (NO) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of Helicobacter pylori to gastric cells.[3]

Trade names

[edit | edit source]

It is marketed in Japan as Stogar by UCB[2] and in India as Lafaxid by Zuventus Healthcare.[3] It is also marketed in South Korea as Ildong Lafutidine by Ildong Pharmaceutical Co Ltd.

References

[edit | edit source]
  1. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ a b UCB Japan Revised: April 2005 Stogar tablets Archived 2014-11-29 at the Wayback Machine
  3. ^ a b c d e Zuventus Healthcare Ltd. India Lafaxid tablets